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Abstract

Alpha-synuclein is the primary constituent of Lewy Bodies, protein aggregates associated
with Parkinson’s Disease, Dementia with Lewy Bodies, and Multiple Systems Dystrophy. Given
the terminal nature of these synucleinopathies, the need for an assay that can report on alphasynuclein aggregation levels in living systems is critical. Western blotting represents one
potential approach to this problem; however, this technique can often be limited by selectivity of
available antibodies and experimental reproducibility. Herein, we describe a novel luminescencebased assay capable of detecting alpha-synuclein solubility in bacterial cells. This platform can
report on the influence of disease-relevant mutations and small molecules. Antibodies are
evaluated for use in Western blotting analysis to complement luminesce assay results.
Preliminary data indicate that improved antibodies/Western blotting procedures are needed in
order to visualize alpha-synuclein expression in this system. Thus, the luminescence-based assay
for alpha-synuclein represents an attractive alternative for monitoring alpha-synuclein solubility
and could ultimately be used to study the influence of mutations and tool compounds on alphasynuclein solubility in living systems.

Key Words: Nanoluciferase, Protein Solubility Assay, Alpha-synuclein, Parkinson’s
Disease
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Introduction

Parkinson’s Disease and other Synucleinopathies
Parkinson’s Disease (PD) is a motor system disorder predominantly characterized by
symptoms such as tremors, rigid movements, bradykinesia, and postural inability. The disease
primarily affects individuals 70 years and older, however symptoms can arise sooner in some
cases.1 PD currently affects 512 people out of 100,000 in the United States over the age of 45. 2
PD is a chronic progressive neurodegenerative disorder, meaning that its symptoms persist and
become worse over an extended period of time due to its ability to reduce the function of neurons
in the Central Nervous System. Brain cells responsible for the production of the neurotransmitter
dopamine either become damaged or die. There is no known cure for the disease, and current
treatment are aimed at alleviating symptoms. Early symptoms are treated with the drugs
levodopa and carbidopa, though the efficacy of the drugs is reduced with time.1 Surgery to
implant microelectrodes for deep brain stimulation, diet, and rehabilitative exercises have been
shown to improve symptoms.3
PD is one of many Synucleinopathies, a group of neurodegenerative diseases that are
often terminal in nature. Synucleinopathies are characterized by mutations and post-translational
modifications to the intrinsically disordered protein alpha-synuclein (aSYN) in select groups of
neurons. aSYN is a protein found to be abundant in the human brain, often found at the presynaptic terminals of neurons. However, mutations and post-translational modifications cause
aSYN to misfold, creating insoluble fibers that ultimately aggregate in association with vesicles
and other components, termed Lewy Bodies (LBs) (Figure 1A-1C).4 LBs have been shown to
impede microtubule formation and cause mitochondrial and nuclear degradation, leading to loss

3
of function in the affected cells.5 LB’s also impede the delivery of dopamine to the substantia
nigra, a portion of midbrain, causing cell death (Figure 1D).6 Having a method for assessing
aSYN aggregation in living systems could provide further insight into the underlying
mechanisms of LB formation including compounds capable of modulating aSYN aggregation.7
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Figure 1 aSYN physiology. (A) aSYN is the primary component of Lewy bodies created as a
result of conformational changes and misfolding mutations. (B) aSYN aggregation can be
induced by oxidative stress, mitochondrial dysfunction, synaptic dysfunction, or inhibition of
ubiquitin/proteasome systems. Misfolded aSYN aggregates into oligomers, fibrils, and
eventually Lewy bodies that are the pathological hallmarks of Parkinson’s disease. (C) Positive
aSYN staining of a Lewy body from a Parkinson’s disease patient. (D) In the healthy human
brain, glucose consumption (red) is readily visible in the substantia nigra. This process is
markedly absent in a brain affected with Parkinson’s. Adapted from Jaiswal, S. et al, Herbal.
Med. 1, 1 (2015), Recchia, A. et al, Neurobiol. Dis. 30, 8 (2008), and Spillantini, M. et al,
Nature. 388, 839 (1997).
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Self-Assembling Split-Nanoluciferase Assay
Traditional methods for detecting aSYN aggregation involve the use of dyes, such
Congo Red and Thioflavin T. However, these compounds only work in vitro rather than in vivo
and are generally unable to report aggregation levels with high enough throughput for effective
chemical, genetic, and chemical testing.8 We have developed a novel luminescence-based assay
monitoring the solubility of aSYN in bacterial cells. This assay relies on the spontaneous
reassembly of NanoLuc luciferase fragments previously described by our lab.9 NanoLuc is a
recently developed small monomeric protein reporter that, when dissected into fragments, is
capable of rapid reassembly and, in turn, production of a luminescent signal. In our assay, the Nterminus fragment consisting of residues 1-65 (N65) is fused with a protein of interest (POI).
Rapid reassembly of N65 with the complementary fragment containing residues 66-171 (66C)
leads to the formation of active NanoLuc and, in turn, a luminescent signal (Figure 2). The
solubility of the POI influences the amount of N65 available for reassembly. Thus, luminescence
signal from the sensor is directly proportional to the solubility of the POI.
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Figure 2. (A) Monitoring aSYN solubility using a split-NanoLuc assay. (A) Non-aggregated
ASYN fused with N-terminus of Nanoluc spontaneously reassembles with the C-terminus of
Nanoluc. Reassembled Nanoluc produces a luminescence signal that is proportional to the
amount of aSYN. The solubility of a protein fused for the N-terminal NanoLuc fragment (N65)
can be readout with the C-terminal Nluc fragment (66C) in living cells. (B) A crystal structure of
Nluc. The N65/66C split halves are highlighted in red and blue, respectively.
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Rationale
The assay shown in Figure 2A has been previously shown to report on the influence of
mutations and small molecules on the solubility of amyloid-beta (Alzheimer’s), huntingtin
(Huntington's), and amylin (type 2 diabetes).9 We have recently re-engineered this assay to
report on changes in aSYN solubility in bacterial cells.10 The goal of this project was to
benchmark these efforts against Western blotting analysis of aSYN expression levels in our
system, which can often be complicated by antibody selectivity and experimental reproducibility.
Thus, we hypothesized that the split-Nluc assay for aSYN solubility may provide a more
reproducible readout of aSYN solubility.

Comparing Western Blotting to the Luminescence Assay
Western Blotting is a technique used to selectively identify a POI from a mixture of
proteins separate on an SDS-PAGE gel. The protein mixture is combined with a loading buffer
such that it can be processed through SDS-PAGE gel. Use of SDS establishes a uniform negative
on the proteins as well as denaturing the proteins (along with heating) such that separation in
dependent upon primary sequence length. Betamercaptoethanol is also added in order to break up
covalent, disulfide bonds.11 The protein mixture can then be separate by size using
electrophoresis (Figure 3).11
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Figure 3. A typical SDS-PAGE gel. The protein mixture is allocated into wells present in the gel
alongside a protein standard ladder for comparative reference. After a charge is applied, proteins
migrate through the gel based on size.

After separation by SDS-PAGE , proteins are transferred to a nitrocellulose membrane,
the membrane is “blocked” by washing it in nonfat dried milk diluted in 1x TBST for several
hours, preventing nonspecific binding of antibodies to the nitrocellulose membrane. A primary
specific to the POI is then incubated with the nitrocellulose membrane. Primary antibody binding
is visualized using a and secondary antibody labeled with horseradish peroxidase allowing for
subsequent imaging of the POI by chemiluminescence imaging. Comparison of the POI band to
the ladder allows for relativistic determination of protein size in kilodaltons (kDa). If protein
samples are normalized for protein content, relative POI band intensities can be compared.
Clearly, this entire protocol is dependent upon the availability of selective antibodies for the POI
as well as reproducibility of transfer, blocking, and incubation steps. We envisioned testing the
reproducibility of Western blotting by growingBL21-Gold (Agilent, #230132) E. coli bacterial
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cells expressing WT-aSYN-N65 and C66 in the absence or presence of known inhibitors of
aSYN aggregation, EGCG12 or D-Mannitol.13 Western blotting results for changes in soluble
aSYN would then be compared to previous luminescence results from the split-NanoLuc assay
(Figure 4).

Figure 4. Observing aSYN solubility with known aggregation inhibitors. (a) EGCG structure (b) Dmannitol structure. Luminescence of bacterial cells expressing WT-αSYN-N65 and 66C in the presence
or absence of the indicated concentration of EGCG (c) or D-mannitol (d). Error bars represent the
standard deviation of three (EGCG) or two (D-Mannitol) biological replicates assayed in triplicate. *
indicates a p-value of <0.05. Adapted from Nelson, T., Truong, T., Truong, B., Bilyeu, C., Zhao, J.,

and Stains, C. (2020).
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Methods

D-Mannitol Media Preparation
Flasks containing TB liquid culture media were prepared according to manufacturer
protocol. D-mannitol was added to the appropriate concentration (0.5M and 1.0 M). Alongside
control TB, the TB with D-mannitol was autoclaved prior to use.
EGCG Media Preparation
EGCG (Cayman Chemical, 70935) was prepared at 100 mM in DMSO.
Cell Culture
BL21-Gold (Agilent, #230132) E. coli bacterial cells expressing WT-aSYN-N65 and 66C
were grown in control TB (5mL) , TB with EGCG (5 mL), and TB with Mannitol (5mL)
overnight with shaking at 37 0C in the presence of both ampicillin (100 μg/mL) and kanamycin
(50 μg/mL). Optical densities were measured at 600 nm (OD600), and the cultures were diluted to
OD600 = 0.1 in the respective media. Cells were grown with shaking at 37 0C until an OD600 =
0.6-0.8 was achieved. IPTG (0.2 mM) and EGCG were induced afterwards, and the cells were
incubated overnight at 16 0C. The following morning, the OD600 was measured and normalized
to 3.0 in 1 mL. Cells were harvested at 700 g for 30 minutes at 40C then lysed with Bacteria
Protein Extraction Reagent (B-PER, 30 μl, Thermo-Fischer). Cells were incubated for 10-15
minutes at room temperature, then centrifuged at 15,000 x g for 5 minutes.
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Western Blotting
Supernatant resulting from the centrifugation were mixed with 3 μl of SDS-PAGE
loading dye (Glycerol, SDS, betamercaptoethanol, bromophenol blue, tris pH = 6.8) and
denatured in boiling water (1000C) for 10 minutes. Samples were centrifuged at 17,000 x g for 5
minutes and cooled to room temperature before being loading on a 12% SDS-PAGE gel
alongside 2 ladders (Novex Sharp Protein Ladder (LC5801), Magic XP Western Ladder
(LC5602) and running at 105 V for 90 minutes. Proteins were transferred onto a nitrocellulose
membrane, using 100 V for 60 minutes. The membrane was blocked using nonfat milk (1g Dry
Milk in 20 mL 1x TBST), then triple-washed with 1x TBST. The membrane was incubated with
the primary antibody (alpha Synuclein Antibody (14H2L1), ABfinityTM Rabbit Monoclonal,
1:1,000) in 5 mL nonfat milk overnight at 40C. After primary antibody incubation, the membrane
was triple-washed with 1x TBST and incubated with the secondary antibody (Goat, Anti-Rabbit
Conjugated HRP, 1:1000) in nonfat milk for 60 minutes. The membrane was developed with
Duraluminol (SuperSignal® West Pico Chemiluminescent Substrate) and imaged using a Gel
Doc XR + System.
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Results and Discussion

Unfortunately, we found that the antibody used in this work was not capable of detecting
aSYN under the conditions described herein. Protein transfer was verified by
chemiluminescence visualization of the Western blot standard (Figure 7A). Staining of the SDSPAGE gel with Coomassie Brilliant Blue (R-250) dye revealed that protein was present in each
lane, although normalization may not have been and should be optimized in future
experiments(Figure 7B). Nonetheless, the absence of bands corresponding to aSYN in Western
blots was highly reproducible under identical conditions with the aforementioned antibodies.
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Figure 7. Western blotting was not capable of detecting aSYN under the experimental
conditions. (A) A Western blot of proteins isolated from BL-21 (Agilent, #230132) E. coli
bacterial cells expressing WT-aSYN-N65 and C66 and was run at 105V for 90 minutes. Proteins
were transferred to a nitrocellulose membrane at 100V for 60 minutes. 10 antibody: alpha
Synuclein Antibody (14H2L1), ABfinityTM Rabbit Monoclonal, 1:1,000. 20 antibody: Goat,
Anti-Rabbit Conjugated HRP, 1:1000. Only bands for the Western blot standard are observed in
lane 2. (B) An SDS-PAGE gel stained with R-250 Coomassie Brilliant Blue dye prior to transfer
to nitrocellulose. Proteins are presents in each lane.
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Summary and Future Direction

In summary, a Western blotting under the experimental conditions described herein was
found to be less reliable that the split-Nluc assay for monitoring changes in aSYN solubility. In
the future, methods and protocols will need to be re-evaluated in order to potentially produce
viable Western blotting results. Coomassie staining reveals that the proteins were successfully
isolated from the cells of interest (Figure 7B), and the presence of a visible ladder on the Western
Blot demonstrates that the proteins were successfully transferred to the membrane.
Troubleshooting could involve screening additional primary antibodies as well as evaluating
different cell extract preparations as previous has shown that aSYN may be expressed in the
periplasm of bacteria.17
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